Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Clinical trial NCT02915016 · COMPLETED
Trial details
- NCT number
- NCT02915016
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-07
- Primary completion
- 2019-08-07
- Enrollment
- 334
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.